AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Relmada Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG003MKSL25
3.27▼ 0.02 (-0.61%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
3.29
Day's Range
3.18 – 3.34
52-Week Range
2.02 – 8.00
Volume
1.1M
Avg Volume
1.4M
Share Statistics
Shares Outstanding
Employees
17
Exchange
XNAS
Listed
2014-03-03
Share count as of August 4, 2026

Relmada Therapeutics, Inc. Common Stock (RLMD) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Relmada Therapeutics, Inc. Common Stock (RLMD)
What is Relmada Therapeutics, Inc. Common Stock's Market Cap?
Relmada Therapeutics, Inc. Common Stock's Market Cap is $348.8M, based on as-reported figures from SEC (XBRL) filings.
What is Relmada Therapeutics, Inc. Common Stock's Enterprise Value?
Relmada Therapeutics, Inc. Common Stock's Enterprise Value is $114.8M, based on as-reported figures from SEC (XBRL) filings.
What is Relmada Therapeutics, Inc. Common Stock's Net Income (TTM)?
Relmada Therapeutics, Inc. Common Stock's Net Income (TTM) is -$58.9M, based on as-reported figures from SEC (XBRL) filings.
What is Relmada Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Relmada Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.55, based on as-reported figures from SEC (XBRL) filings.
What is Relmada Therapeutics, Inc. Common Stock's Net Debt?
Relmada Therapeutics, Inc. Common Stock's Net Debt is -$234.0M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RLMDAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other (expenses) income:
Interest/investment income, net
Realized (loss) gain on short-term investments
Unrealized (loss) gain on short-term investments
Total other income
Net loss
Loss per common share – basic (in Dollars per share)
Loss per common share – diluted (in Dollars per share)